masteron cycle

Posted on08/24/2016 in Articles

Prevention and elimination of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy, and postoperative nausea and vomiting.

Hypersensitivity masteron cycle to any component of the drug, pregnancy and lactation.Children under 2 years (safety and efficacy has not been studied)

Dosage and administration: Nausea and vomiting with cytotoxic chemotherapy or radiotherapy Choice dosage regimen is determined by the emetogenic anticancer therapy. For adults, the daily dose usually is 8-32 mg are recommended the following modes. For moderate emetogenic chemotherapy or radiotherapy:

8 mg of ondansetron for 1-2 hours prior to the primary therapy, followed by taking further 8 hours after 12 mg.

When vysokoemetogennoy chemotherapy: The recommended dose is 24 mg in conjunction with dexamethasone sodium phosphate orally at a dose of 12 mg 1-2 hours before the start of chemotherapy.
For the prevention of late or prolonged vomiting occurring within 24 hours, you should continue taking Zofran syrup at a dose of 8 mg two once a day for 5 days. Children Zofran usually administered as a single solution for intravenous injection immediately before chemotherapy, followed by ingestion of a dose of 4 mg every 12 hours. After completion of chemotherapy is necessary to continue taking the syrup Zofran 4 mg twice a day for 5 days. Nausea and vomiting in the postoperative period Adults For the prevention of nausea and vomiting in postoperative period, we recommend taking 16 mg masteron cycle inside 1 hour prior to anesthesia. For relief posleperatsionnoy nausea and vomiting is used Zofran injection. Children for the prevention and treatment of postoperative nausea and vomiting in children is administered as an intravenous injection. Elderly patients dosage change is required. Patients with renal insufficiency No special dosage changes receive frequencies or route of administration. Patients with hepatic impairment The daily dose of ondansetron should not exceed 8 mg per day. Patients with slow metabolism of sparteine / debrisokvina. Correction of daily dosage or frequency of administration of ondansetron are required.

Side effects: Allergic reactions: urticaria, bronchospasm, laryngospasm, angioedema, anaphylaxis. From the digestive system: hiccups, dry mouth, and constipation or diarrhea, sometimes asymptomatic transient increase in liver tests. Since the cardiovascular system: chest pain in some cases with ST-segment depression, arrhythmia, bradycardia, decreased blood pressure. from the nervous system:headache, dizziness, spontaneous movement disorders and seizures. Other: facial flushing, burning sensation, temporary disruption of visual acuity, gipoka- Liem, hypercreatininemia.

Overdose
There is limited experience of ondansetron overdose. In most cases, the symptoms are similar to the side effects of using the drug at the recommended doses. Treatment: the specific antidote for Zofran not therefore recommended symptomatic and supportive therapy for suspected overdose. Use  ipecac should not be an overdose, as its effectiveness is unlikely due to the anti-emetic action of masteron cycle.

Interaction with other drugs
There is no evidence that ondansetron induces or inhibits the metabolism of other drugs commonly prescribed in combination with it.
Ondansetron is metabolized by several cytochrome P450 enzyme system. Inhibition or reduction of activity of an enzyme is typically compensated by other normal, due to the significant decrease than the total clearance of ondansetron unlikely. Nevertheless, caution is required when used together.

Special studies have shown that ondansetron does not interact with alcohol, temazepam, furosemide, tramadol and propofol (Diprivan).

Cautions
noted allergic reaction to ondansetron in patients with a history of hypersensitivity to other antagonists of the 5HT 3 receptor.
Since ondansetron increases the passage of the contents on the large intestine, patients with signs of intestinal obstruction after treatment require regular monitoring.
Tablets for sucking contain aspartame, and therefore they should be used with caution in patients with phenylketonuria.
Tablets for resorption should not be squeezed out of the foil. The tablets from the packaging should take immediately before use.

Composition
Tablets for sucking 4 mg and 8 mg. 10 tablets in a blister pack of the five-layer laminate of aluminum / PVC foil. 1 blister with instructions for use in a carton box.

Shelf life
3 years.
Do not use after the expiration date printed on the package.

Storage conditions
List B. The temperature is below 30 ° C out of reach of children. how much to inject for weight loss

hcg diet

shots for weight loss reviews